Mary-Kate Malecek

6PUBLICATIONS
50CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 25, 2023
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.

Kevin A David, Suchitra Sundaram, Seo-Hyun Kim

|Sep 27, 2021
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.

Victor Manuel Orellana-Noia, Daniel R Reed, Ashley Alesia McCook

|Sep 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.

David A Bond, Jeffrey M Switchenko, Diego Villa

|Aug 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.

Victor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek

|Jun 06, 2020
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.

Mary-Kate Malecek, Marcus P Watkins, Nancy L Bartlett

|Jul 19, 2017
Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.

Mary-Kate Malecek, Adam M Petrich, Shaina Rozell

Pageof 1

Frequent Collaborators

3 joint publications

Natalie Sophia Grover

3 joint publications

Reem Karmali

3 joint publications

Jordan Carter

2 joint publications

Narendranath Epperla